Overview & Definition
Myelodysplastic Syndromes (MDS) are a group of bone marrow stem cell disorders where the bone marrow produces poorly formed or dysfunctional blood cells, often leading to severe cytopenias and potential transformation into Acute Myeloid Leukemia (AML).
Types & Classification
- MDS with Single Lineage Dysplasia
- MDS with Multilineage Dysplasia
- MDS with Ring Sideroblasts
- MDS with Excess Blasts (MDS-EB1 / MDS-EB2)
- MDS associated with Isolated del(5q)
Underlying Causes & Risk Factors
- Age-related gene mutations
- Prior exposure to chemotherapy or radiation therapy
- Environmental toxins (Benzene)
Common Symptoms & Warning Signs
Diagnostic Evaluation
Accurate diagnosis requires comprehensive laboratory investigation under expert hematological supervision:
- 🔍 Complete Blood Count & Reticulocyte Count
- 🔍 Bone Marrow Aspiration & Trephine Biopsy examining dysplastic changes
- 🔍 Cytogenetic Karyotyping (del 5q, monosomy 7, trisomy 8)
- 🔍 Next-Generation Sequencing (NGS) Gene Panel
Treatment Options & Clinical Management
- 💊 Erythropoiesis-Stimulating Agents (ESAs) & Erythroid Maturation Agents (Luspatercept) – first-line for lower-risk MDS anemia and MDS with ring sideroblasts.
- 💊 Targeted Immunomodulatory Therapy (Lenalidomide) – indicated specifically for lower-risk MDS with isolated del(5q) cytogenetic abnormality.
- 💊 Hypomethylating Agents (Azacitidine / Decitabine / Oral Decitabine-Cedazuridine) – disease-modifying therapy for higher-risk MDS.
- 💊 Blood & Platelet Transfusion Support with Iron Chelation – managing symptomatic cytopenias and iron overload.
- 💊 Allogeneic Hematopoietic Stem Cell Transplant – potential curative therapy for eligible higher-risk MDS patients.
Frequently Asked Questions
Early indicators include persistent anemia-related fatigue, shortness of breath on mild exertion, pale skin, frequent bacterial infections (from neutropenia), and easy bruising or pinpoint petechiae (from thrombocytopenia).
Diagnosis requires a complete blood count and peripheral blood smear, bone marrow aspiration & trephine biopsy (evaluating dysplastic cellularity and blast count), conventional cytogenetics (karyotyping for del 5q, monosomy 7, trisomy 8), and targeted Next-Generation Sequencing (NGS) to risk-stratify patients via IPSS-M / IPSS-R systems.